PD-1单抗Opdivo-话题@MedSci - 梅斯（MedSci）

#PD-1单抗Opdivo#

16篇内容 | 1081人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621287, encodeId=123c162128ec3, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=221346, objectId=ab662213469b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab662213469b, replyNumber=0, likeNumber=44, createdTime=2021-12-02, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab662213469b, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ab662213469b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621286, encodeId=2d4916212863e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审, objectType=article, longId=202354, objectId=f8f120235495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f120235495, replyNumber=0, likeNumber=73, createdTime=2020-10-23, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f120235495, moduleTitle=PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f8f120235495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621285, encodeId=60a416212850e, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, objectType=article, longId=201929, objectId=558820192924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=558820192924, replyNumber=0, likeNumber=98, createdTime=2020-10-12, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=558820192924, moduleTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=558820192924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621284, encodeId=31f71621284d8, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, objectType=article, longId=198728, objectId=a9fa198e28d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9fa198e28d9, replyNumber=0, likeNumber=68, createdTime=2020-08-06, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9fa198e28d9, moduleTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a9fa198e28d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621283, encodeId=2d5c162128311, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, objectType=article, longId=195725, objectId=0297195e2587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0297195e2587, replyNumber=0, likeNumber=70, createdTime=2020-06-13, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0297195e2587, moduleTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0297195e2587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621282, encodeId=8230162128234, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=0, createdTime=2020-05-18, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621281, encodeId=c8931621281f8, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, objectType=article, longId=194237, objectId=1da819423ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da819423ef7, replyNumber=0, likeNumber=61, createdTime=2020-05-17, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da819423ef7, moduleTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1da819423ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621280, encodeId=80ab16212808f, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, objectType=article, longId=189902, objectId=b3c0189902f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3c0189902f2, replyNumber=0, likeNumber=78, createdTime=2020-03-14, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3c0189902f2, moduleTitle=PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b3c0189902f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621279, encodeId=00ce16212e90b, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, objectType=article, longId=188791, objectId=aa9f188e91bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa9f188e91bf, replyNumber=0, likeNumber=63, createdTime=2020-02-27, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa9f188e91bf, moduleTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aa9f188e91bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621278, encodeId=076e16212e8bd, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, objectType=article, longId=188481, objectId=680d18848160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=680d18848160, replyNumber=0, likeNumber=64, createdTime=2020-02-22, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=680d18848160, moduleTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=680d18848160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621277, encodeId=c08e16212e753, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, objectType=article, longId=188280, objectId=62191882804d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62191882804d, replyNumber=0, likeNumber=71, createdTime=2020-02-19, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62191882804d, moduleTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=62191882804d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621276, encodeId=beab16212e654, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, objectType=article, longId=186455, objectId=16dd186455e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16dd186455e4, replyNumber=0, likeNumber=68, createdTime=2020-01-19, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16dd186455e4, moduleTitle=FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=16dd186455e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621275, encodeId=b51c16212e533, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=58, createdTime=2019-10-25, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621274, encodeId=50bf16212e4c0, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=59, createdTime=2019-09-07, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621273, encodeId=4fc916212e361, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望, objectType=article, longId=164164, objectId=4afe164164c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4afe164164c6, replyNumber=0, likeNumber=92, createdTime=2019-04-14, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4afe164164c6, moduleTitle=PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4afe164164c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621272, encodeId=d4fe16212e24f, content=<a href='/topic/show?id=5f1f139091f' target=_blank style='color:#2F92EE;'>#PD-1单抗Opdivo#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, objectType=article, longId=158911, objectId=f601158911df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f601158911df, replyNumber=0, likeNumber=72, createdTime=2019-01-27, rootId=0, userName=ymljack, userId=bc4a20243913, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f601158911df, moduleTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f601158911df)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1单抗Opdivo

2020-05-29

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2021-12-02

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审

2020-10-23

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益

2020-10-12

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期

2020-08-06

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌

2020-06-13

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2020-05-18

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％

2020-05-17

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌，获得FDA的加速批准

2020-03-14

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

BMS的PD-1单抗Opdivo首次获批治疗食道癌

2020-02-27

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败

2020-02-22

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％

2020-02-19

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

FDA将对PD-1单抗Opdivo联合CTLA-4单抗Yervoy用作非小细胞肺癌的一线治疗，展开优先审查

2020-01-19

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-10-25

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

PD-1单抗Opdivo用作小细胞肺癌的维持免疫疗法，临床试验结果令人失望

2019-04-14

ymljack (审核中...)

前往app查看评论内容

#PD-1单抗Opdivo#

百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧

2019-01-27

科室
- - 订阅+
  - 更多科室
工具
服务